13F filer · CIK 1493215
RTW INVESTMENTS, LP
NEW YORK, NY · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$11.7B
+$1.7B vs prior
Positions
84
New / sold out
9 / 13
Added / reduced
26 / 8
Turnover
10.3%
buys $1.2B · sells $1.1B
Top-10 weight
47.7%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | KAILERA THERAPEUTICS INC | +10,776,820 | – | +$237.4M |
| Added | ULTRAGENYX PHARMACEUTICAL IN | +4,148,100 | +113.7% | +$138.5M |
| Added | CG ONCOLOGY INC | +1,529,782 | +21.9% | +$108.7M |
| Added | ORUKA THERAPEUTICS INC | +1,080,882 | +52.5% | +$102.9M |
| New | STRUCTURE THERAPEUTICS INC | +1,607,507 | – | +$86.3M |
| Added | UNIQURE NV | +1,355,216 | +52.4% | +$62.4M |
| Added | IRHYTHM HOLDINGS INC | +514,131 | +30.8% | +$61.2M |
| New | AXOGEN INC | +1,011,576 | – | +$46.7M |
| New | DANAHER CORP DEL | +230,000 | – | +$43.8M |
| New | SOLID BIOSCIENCES INC | +3,892,926 | – | +$38.9M |
25 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | APOGEE THERAPEUTICS INC | -2,782,097 | -100.0% | $-234.2M |
| Sold out | APELLIS PHARMACEUTICALS INC | -3,685,045 | -100.0% | $-148.2M |
| Reduced | COGENT BIOSCIENCES INC | -3,149,654 | -57.7% | $-121.9M |
| Reduced | HINGE HEALTH INC | -1,430,000 | -74.1% | $-118.7M |
| Sold out | INTUITIVE SURGICAL INC | -220,000 | -100.0% | $-101.4M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -2,054,175 | -100.0% | $-81.6M |
| Reduced | NATERA INC | -250,000 | -20.0% | $-67.9M |
| Sold out | CRINETICS PHARMACEUTICALS IN | -1,451,326 | -100.0% | $-52.7M |
| Sold out | WAYSTAR HLDG CORP | -1,630,000 | -100.0% | $-39.3M |
| Sold out | ARROWHEAD PHARMACEUTICALS IN | -585,682 | -100.0% | $-36.7M |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | MADRIGAL PHARMACEUTICALS INCCOM | 1,993,687 | $1.1B | 9.14% |
| 2 | ARGENX SESPONSORED ADR | 709,446 | $658.2M | 5.62% |
| 3 | PTC THERAPEUTICS INCCOM | 7,746,415 | $631.9M | 5.39% |
| 4 | PROTAGONIST THERAPEUTICS INCCOM | 5,061,175 | $620.4M | 5.30% |
| 5 | CG ONCOLOGY INCCOM | 8,514,590 | $605.0M | 5.16% |
| 6 | INSMED INCCOM PAR $.01 | 4,842,880 | $516.3M | 4.41% |
| 7 | TANGO THERAPEUTICS INCCOM | 13,900,620 | $434.5M | 3.71% |
| 8 | SPYRE THERAPEUTICS INCCOM NEW | 4,251,996 | $377.5M | 3.22% |
| 9 | CELCUITY INCCOM | 3,304,903 | $345.8M | 2.95% |
| 10 | ERASCA INCCOM | 17,946,754 | $328.8M | 2.81% |
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.